All posts by KAVALJIT SINGH

COVID-19: A Triple Whammy for Emerging Market and Developing Economies

By Kavaljit Singh | Briefing Paper # 36 | April 23, 2020

Even though the rapid spread of the novel coronavirus (COVID-19) pandemic in the US and European Union has captured the world’s attention, one should not lose sight of the pandemic and its associated health, economic and financial stability challenges in the rest of the world. As the COVID-19 pandemic advances globally, Africa and South Asia are witnessing a surge in the number of new cases lately, and these regions could soon become its next epicenters in the coming weeks….

Read More |

COVID-19: Challenges Before the G20 Trade Ministers

By Biswajit Dhar | Briefing Paper # 35 | April 5, 2020

Trade Ministers from G20 countries met on 30th March, days after the heads of states and governments of the major economies for an Extraordinary Summit meeting, to take a coordinated stand in response to the COVID-19 pandemic. In these extraordinary times, the Trade Ministers agreed that the “international community to step up cooperation and coordination to protect human life and lay the foundations for a strong economic recovery and a sustainable, balanced, and inclusive growth.”

In times when…

Read More |

Coronavirus Triggers Large Capital Outflows from India

By Kavaljit Singh | Policy Brief # 6 | April 3, 2020

In March 2020, foreign investors pulled out a record Rs.1182 billion (US$16 bn) from the Indian financial markets as the spread of coronavirus (COVID-19) pandemic triggered panic selling across all emerging markets. As per official data released by the National Securities Depository Limited (NSDL), foreign portfolio investors (FPIs) and foreign institutional investors (FIIs) together pulled out Rs.619 bn ($8.3 bn) from the equity segment and Rs.603 bn ($8.1 bn) from the debt segment in March (see Table 1).

The capital…

Read More |

An Open Letter to Gilead Demanding Affordability and Access to Remdesivir

By CSOs | Letter | March 30, 2020

In an open letter to Daniel O’Day, Chief Executive Officer of Gilead Science, more than 150 organisations (including Madhyam) and individuals have urged the US biotechnology company not to enforce exclusivity over remdesivir, an experimental drug seen as a potential treatment for COVID-19 patients. The clinical trials for remdesivir are underway in China and elsewhere in Asia to test its effectiveness in treating coronavirus infections. Since Gilead currently holds all patents for the development and production of remdesivir, the…

Read More |

The Best of Two Worlds? The Brazil-India Investment Treaty

By Martin Dietrich Brauch | Guest Blog | March 30, 2020

Two innovative investment treaty models developed by major emerging economies came to light in 2015 when Brazil concluded its first Cooperation and Facilitation Investment Agreements (CFIAs, or ACFIs, in its Portuguese-language abbreviation) marriage between the two: on…

Read More |